Okay, thank you.
Does anybody else want to comment? No? Okay.
My second question, then, is about the common drug review currently expanding to cover, or thinking of expanding to cover, new indications for older or previous drugs, and eventually plans to cover all publicly covered drugs. Can you tell me the impact you think that will have on cost savings for the federal drug benefit plan?